Fulcrum Therapeutics Inc FULC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!
-
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!
-
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!
-
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!
-
Trending: Fulcrum Therapeutics, Sanofi in Losmapimod Licensing Deal
-
Fulcrum Therapeutics, Sanofi Ink Losmapimod Licensing Deal
Trading Information
- Previous Close Price
- $4.00
- Day Range
- $3.77–4.23
- 52-Week Range
- $2.87–13.70
- Bid/Ask
- $3.79 / $3.99
- Market Cap
- $235.25 Mil
- Volume/Avg
- 1.9 Mil / 1.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.90
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 89
- Website
- https://www.fulcrumtx.com
Comparables
Valuation
|
Metric
|
FULC
|
AXSM
|
ALEC
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.86 | 41.66 | 3.18 |
Price/Sales | 2.90 | 14.57 | 7.99 |
Price/Cash Flow | — | — | — |
Price/Earnings
FULC
AXSM
ALEC
Financial Strength
|
Metric
|
FULC
|
AXSM
|
ALEC
|
|---|---|---|---|
Quick Ratio | 21.84 | 2.34 | 3.41 |
Current Ratio | 22.07 | 2.48 | 3.52 |
Interest Coverage | — | −79.61 | — |
Quick Ratio
FULC
AXSM
ALEC
Profitability
|
Metric
|
FULC
|
AXSM
|
ALEC
|
|---|---|---|---|
Return on Assets (Normalized) | −1.76% | −32.79% | −19.88% |
Return on Equity (Normalized) | −1.91% | −96.25% | −77.59% |
Return on Invested Capital (Normalized) | −1.83% | −48.34% | −62.79% |
Return on Assets
FULC
AXSM
ALEC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Wywyphfv | Fnbf | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Crdhzxjwv | Tnldsd | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Drzfbsyt | Qtqdbf | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vshvrpf | Ndysv | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Shhxdws | Sfrdl | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Dzpcptk | Qrd | $28.1 Bil | |||
| Moderna Inc
MRNA
| Vmxsqdwj | Myzh | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Qcjxxgh | Tfcj | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Wxszhrpf | Tpldswf | $13.4 Bil | |||
| Incyte Corp
INCY
| Lkcfxwdf | Swbqcb | $12.7 Bil |
United States